Nephrotoxic aspects of cyclosporine

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Over the last 20 years cyclosporine (CsA) has improved the survival of kidney, heart, and liver transplants. However, with increasing use, evidence has accumulated that CsA therapy carries a variety of side effects, the most important being renal toxicity. CsA can lead to a wide spectrum of renal function impairments, including a marked and rapidly reversible decrease in renal hemodynamics (acute CsA nephrotoxicity), and a chronic form of renal damage that potentially progress irreversibly to end-stage renal disease (chronic CsA nephrotoxicity). All these manifestations are the consequence of the drug toxic effects on renal vessels and the tubulointerstitium. A proper diagnosis of CsA toxicity at early stages, the combination of low CsA doses with non-nephrotoxic immunosuppressants, and the development of more feasible strategies to monitor daily CsA exposure may contribute to a better CsA management, improve quality of life of transplant recipients, and prolong graft survival.

Original languageEnglish
JournalTransplantation Proceedings
Volume36
Issue number2 SUPPL.
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Cyclosporine
Kidney
Poisons
Graft Survival
Immunosuppressive Agents
Chronic Kidney Failure
Hemodynamics
Quality of Life
Transplants
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Nephrotoxic aspects of cyclosporine. / Cattaneo, D.; Perico, N.; Gaspari, F.; Remuzzi, G.

In: Transplantation Proceedings, Vol. 36, No. 2 SUPPL., 03.2004.

Research output: Contribution to journalArticle

@article{8a53ab843a2d44b49f19b631534fb5d7,
title = "Nephrotoxic aspects of cyclosporine",
abstract = "Over the last 20 years cyclosporine (CsA) has improved the survival of kidney, heart, and liver transplants. However, with increasing use, evidence has accumulated that CsA therapy carries a variety of side effects, the most important being renal toxicity. CsA can lead to a wide spectrum of renal function impairments, including a marked and rapidly reversible decrease in renal hemodynamics (acute CsA nephrotoxicity), and a chronic form of renal damage that potentially progress irreversibly to end-stage renal disease (chronic CsA nephrotoxicity). All these manifestations are the consequence of the drug toxic effects on renal vessels and the tubulointerstitium. A proper diagnosis of CsA toxicity at early stages, the combination of low CsA doses with non-nephrotoxic immunosuppressants, and the development of more feasible strategies to monitor daily CsA exposure may contribute to a better CsA management, improve quality of life of transplant recipients, and prolong graft survival.",
author = "D. Cattaneo and N. Perico and F. Gaspari and G. Remuzzi",
year = "2004",
month = "3",
doi = "10.1016/j.transproceed.2004.01.011",
language = "English",
volume = "36",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Nephrotoxic aspects of cyclosporine

AU - Cattaneo, D.

AU - Perico, N.

AU - Gaspari, F.

AU - Remuzzi, G.

PY - 2004/3

Y1 - 2004/3

N2 - Over the last 20 years cyclosporine (CsA) has improved the survival of kidney, heart, and liver transplants. However, with increasing use, evidence has accumulated that CsA therapy carries a variety of side effects, the most important being renal toxicity. CsA can lead to a wide spectrum of renal function impairments, including a marked and rapidly reversible decrease in renal hemodynamics (acute CsA nephrotoxicity), and a chronic form of renal damage that potentially progress irreversibly to end-stage renal disease (chronic CsA nephrotoxicity). All these manifestations are the consequence of the drug toxic effects on renal vessels and the tubulointerstitium. A proper diagnosis of CsA toxicity at early stages, the combination of low CsA doses with non-nephrotoxic immunosuppressants, and the development of more feasible strategies to monitor daily CsA exposure may contribute to a better CsA management, improve quality of life of transplant recipients, and prolong graft survival.

AB - Over the last 20 years cyclosporine (CsA) has improved the survival of kidney, heart, and liver transplants. However, with increasing use, evidence has accumulated that CsA therapy carries a variety of side effects, the most important being renal toxicity. CsA can lead to a wide spectrum of renal function impairments, including a marked and rapidly reversible decrease in renal hemodynamics (acute CsA nephrotoxicity), and a chronic form of renal damage that potentially progress irreversibly to end-stage renal disease (chronic CsA nephrotoxicity). All these manifestations are the consequence of the drug toxic effects on renal vessels and the tubulointerstitium. A proper diagnosis of CsA toxicity at early stages, the combination of low CsA doses with non-nephrotoxic immunosuppressants, and the development of more feasible strategies to monitor daily CsA exposure may contribute to a better CsA management, improve quality of life of transplant recipients, and prolong graft survival.

UR - http://www.scopus.com/inward/record.url?scp=1642268247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642268247&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2004.01.011

DO - 10.1016/j.transproceed.2004.01.011

M3 - Article

C2 - 15041344

AN - SCOPUS:1642268247

VL - 36

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 2 SUPPL.

ER -